Physician profile
Jay M Rhee
NPI 1568490852
$9,068.45
in general payments reported to CMS, 2019-2025
67 companies · $3,319 in 2025
The $3,319 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $353 · 2021: $1,236 · 2022: $719 · 2023: $994 · 2024: $1,338 · 2025: $3,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,661 · Travel and Lodging: $764 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,660.61 |
| Travel and Lodging | $764.00 |
| Education | $225.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alphatec Spine, INC | $764.00 | 2025 | Other - Miscellaneous |
| Pfizer INC. | $695.35 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $600.07 | 2019-2025 | Enhertu, Tagrisso, Lynparza |
| Novartis Pharmaceuticals Corporation | $541.66 | 2019-2025 | |
| Stryker Corporation | $519.06 | 2021 | |
| Merck Sharp & Dohme LLC | $502.15 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Daiichi Sankyo INC. | $383.43 | 2019-2025 | Enhertu, Vanflyta, Datroway |
| Abbvie INC. | $379.36 | 2019-2025 | |
| Seagen INC. | $337.48 | 2019-2023 | Padcev |
| Genzyme Corporation | $306.15 | 2019-2025 | |
| Amgen INC. | $265.14 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Gilead Sciences, INC. | $247.40 | 2019-2025 | Trodelvy |
| Eisai INC. | $224.13 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $215.59 | 2019-2023 | Imbruvica |
| Genentech USA, INC. | $180.40 | 2019-2025 | Phesgo, Polivy, Lunsumio |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $162.81 | 2021-2025 | Libtayo |
| Incyte Corporation | $162.37 | 2019-2025 | Monjuvi, Jakafi, Zynyz |
| Smith+Nephew, INC. | $148.54 | 2023 | Stravix, Grafix |
| E.R. Squibb & Sons, L.L.C. | $144.60 | 2019-2023 | Opdivo |
| Asd Specialty Healthcare, LLC | $139.87 | 2022 | |
| Glaxosmithkline, LLC. | $115.21 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Ethicon US, LLC | $114.25 | 2019 | |
| Janssen Biotech, INC. | $108.61 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| Epizyme, INC. | $99.82 | 2021-2023 | Tazverik |
| Beone Medicines USA, INC. | $93.00 | 2025 | Tevimbra, Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $91.33 | 2019-2024 | Fruzaqla |
| Kite Pharma, INC. | $86.61 | 2021-2025 | Yescarta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.16 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.05 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $76.88 | 2021-2024 | Ultomiris |
| Astellas Pharma US INC | $76.15 | 2019-2023 | Padcev, Xospata |
| Celgene Corporation | $73.16 | 2019-2025 | Breyanzi, Opdualag |
| Array Biopharma INC | $67.25 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Janssen Pharmaceuticals, INC | $67.20 | 2019-2022 | |
| Beigene USA, INC. | $62.65 | 2020-2024 | Brukinsa |
| Exelixis INC. | $61.09 | 2021-2024 | Cabometyx |
| Lilly USA, LLC | $60.63 | 2019-2025 | Verzenio, Jaypirca |
| Adc Therapeutics America, INC. | $57.74 | 2022-2024 | |
| Adaptive Biotechnologies Corporation | $50.19 | 2025 | Clonoseq |
| Mirati Therapeutics, INC. | $39.93 | 2023 | Krazati |
| Geron Corporation | $39.85 | 2025 | Rytelo |
| Rigel Pharmaceuticals, INC. | $38.45 | 2020-2023 | Tavalisse, Rezlidhia |
| Agios Pharmaceuticals, INC. | $36.16 | 2023-2024 | Pyrukynd |
| Karyopharm Therapeutics INC. | $32.49 | 2020-2024 | Xpovio |
| Deciphera Pharmaceuticals INC. | $28.42 | 2025 | Qinlock, Romvimza |
| Tersera Therapeutics LLC | $27.48 | 2024 | Zoladex |
| Iovance Biotherapeutics, INC. | $26.55 | 2025 | Amtagvi |
| Lexicon Pharmaceuticals, INC. | $26.16 | 2019 | |
| Pharmaessentia USA Corporation | $24.67 | 2025 | Besremi |
| Emd Serono, INC. | $24.37 | 2025 | |
| Tesaro, INC. | $22.45 | 2019 | |
| Legend Biotech USA INC. | $22.34 | 2025 | Carvykti |
| Syndax Pharmaceuticals, INC. | $19.98 | 2025 | |
| Fennec Pharmaceuticals, INC. | $19.33 | 2025 | Fyarro |
| Dova Pharmaceuticals | $18.56 | 2021 | |
| Spectrum Pharmaceuticals INC. | $18.39 | 2024 | Rolvedon |
| Helsinn Therapeutics (U.S.), INC. | $17.70 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.63 | 2021 | |
| Novocure INC. | $15.71 | 2025 | Optune Lua (Novottf-200t) |
| Verastem, INC. | $15.68 | 2019 | |
| Servier Pharmaceuticals LLC | $15.41 | 2023 | |
| Recordati_rare_diseases_inc. | $14.96 | 2024 | Sylvant |
| Secura Bio, INC. | $14.67 | 2021 | |
| Portola Pharmaceuticals, LLC | $14.59 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $12.95 | 2019 | |
| Cti Biopharma Corp. | $12.64 | 2022 | |
| Octapharma USA, INC. | $12.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Rhee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.